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ABSTRACT
FOOD ELIMINATION BASED ON ALCAT TESTING AND THE EFFECT ON OVERALL
BODY INFLAMMATION
Dawn Michelle Herbig, M.S.
School of Family, Consumer & Nutrition Sciences
Northern Illinois University, 2014
Judith Lukaszuk, Thesis Director

Background: Growing evidence suggests that obesity is associated with systemic inflammation.
The level of inflammation can be exacerbated by one or more existing food intolerances.
Furthermore, studies have shown that diet quality, not quantity, plays an important role in
potential inflammation caused by foods. It is therefore, important to determine if dietary patterns
alone or in combination with increased adiposity have a greater effect on systemic inflammation
and body composition.
Objective: Hence, the purpose of this study is was to examine the effect of food elimination
using the ALCAT food elimination protocol, on body composition and overall body
inflammatory markers.
Methods: One hundred thirty-one participants were randomly assigned to either a treatment
(n=72) or a control (n=59) group in this pre- and post-test double blind experimental study. All
participants followed a 4-week elimination diet based on ALCAT testing protocol, completed a
medical symptoms questionnaire at the beginning and end of the study, had their blood drawn for
inflammatory markers and provided anthropometric measurements for body composition
analysis.. In additions Participants kept an exercise log and food log during the study. Within and
between group differences in body composition and inflammatory markers were analyzed using

repeated measures ANOVA. Significant main and interaction effects were analyzed using the
Bonferonni post-hoc method for multiple comparisons. Univariate analysis of variance was
utilized to examine body composition.
Results: Both the treatment group and the control groups experienced significant decreases in
CRP, MPO, and TNF-α; yet there were no statistically significant differences between the
treatment and the control groups. However, the treatment group was found to have a significant
(p<0.05) decrease in SAA compared with the control group which showed no change in SAA.
Analysis of body composition revealed a significant (p<0.05) decrease in lean body mass, body
fat percentage, and waist circumference in both groups; however, the difference was not
statistically different between the treatment and the control group even after adjustments for age,
gender and baseline outcomes.
Conclusions: Overall, there was little evidence to support the ability of elimination diets in
decreasing total body inflammation or altering body composition using ALCAT testing protocol.
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CHAPTER 1

INTRODUCTION

Background
Over the last 20 years, there has been a dramatic rise in body weight. Currently, more
than one third of adults in the United States are obese (1). Obesity is a major health concern,
since it is strongly linked to coronary heart disease, insulin resistance, type 2 diabetes and nonalcoholic fatty liver disease (1,2). Although the rise in obesity has many causes, inflammation is
the most common feature which has been implicated in the pathophysiology of all the obesity
related disorders.
Inflammation is a protective response by the immune system to harmful stimuli, such as
infection, acute illness, trauma, toxins, many chronic diseases and physical stress (2). Chronic
inflammation is characterized by the prolonged presence of macrophages in the injured tissue,
simultaneously destroying and healing the tissue during the inflammatory process (3-5). Chronic
inflammation can lead to systemic inflammation which can impair digestion and absorption
which can result in a decreased lean body mass and a decline in nutritional status (2,5). The role
of inflammation in the pathology of rheumatoid arthritis (RA), inflammatory bowel diseases
(IBD), and asthma are well recognized (5). Yet when obesity is present, the role of inflammation
and the contribution to pathology of disease along with other factors, like nutrition, is less clear
(5).
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Numerous studies have shown that as visceral adipose tissue increases with weight gain
so do pro-inflammatory cytokines such as C-reactive protein (CRP),interleukin 1-beta (IL-1-β),
interleukin-6 (IL-6),myeloperoxidase (MPO), and tumor necrosis factor-alpha (TNF-α). The
cascade of pro-inflammatory cytokines favors insulin resistance which may lead to more weight
gain as fat. It becomes a vicious cycle of increased inflammation and more deposition as fat (68). Furthermore, the multitude of cytokines released in relation to obesity can change from
advantageously protecting the body to damaging by leading to inflammatory diseases (2,4,5).
The nutritional state of an individual can also affect inflammation. For example, undernutrition,
which may occur with impaired digestion or absorption, dysfunctional metabolic processing or
inadequate intake, can result in malnutrition and protein depletion (2). On the other hand,
overnutrition promotes obesity-related health issues, such as diabetes, heart disease,
hypertension, metabolic syndrome, and some cancers (2).
Along with nutritional status, dietary intake may play a key role in the inflammatory
process. Simple diet and lifestyle changes can positively affect obesity-related inflammation
(2,9). Likewise, the level of inflammation can be exacerbated by one or more existing food
intolerances. If food intolerance is present, it stimulates the fight or flight response and increases
your cravings for that food. This in turn, promotes the greater consumption of that food which
will lead to more inflammation. Continued exposure to intolerances provides constant proinflammatory stimuli that increase the body’s inflammatory response resulting in tissue damage
and loss of barrier function thus leading to systemic inflammation (5,10). What is unknown at
this time is if one eliminates food intolerances from the diet will their systemic inflammation, as
measured through CRP, IL-1β, IL-6, MPO and TNF-α, decrease, thereby, reducing insulin
resistance thus enabling them to lose weight.
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Antigen Leukocyte Cellular Antibody Test (ALCAT) is useful is identifying problematic
foods in cell-mediated or delayed reactions (2). ALCAT diets require the elimination of
intolerant foods and thus should decrease appetite, reduce systemic inflammation, enable weightloss and improve body composition (11).
Body composition measurements are important in assessing fat mass (FM) and lean body
mass (LBM) (12). FM includes essential and non-essential fats. LBM includes protein, water,
carbohydrate, and minerals (12). Waist circumference (WC) measurement indicate regional body
fat distribution and has been shown to correlate with visceral adipose tissue (12).

Statement of the Problem
The purpose of this study was to examine the effect food elimination will have on body
composition and on body inflammatory markers using ALCAT testing.

Independent Variables
A food elimination diet based on ALCAT test results (treatment group) or a sham list of
foods (placebo group) will be provided and followed for four weeks.

Dependent Variables
Body composition will be measured in relation to food elimination using FFM, LBM,
body fat percent, abdominal WC, and fat mass for both pre- and post-4 week study.
Body inflammatory markers such as CRP, IL-1-β, IL-6, MPO, SAA, and TNF-α will be
measured via blood test performed at the NIU Nutrition Lab.
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Hypotheses
The following hypotheses were investigated during the 4-week elimination program:
1.

Subjects randomly assigned to the ALCAT treatment group will have lower CRP at the
end of the 4 week study compared to those receiving the placebo.
Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: Body inflammatory markers
Attribute: Comparison of pre- and post-study blood levels of CRP

2.

Subjects randomly assigned to the ALCAT treatment group will have lower IL-1-β at the
end of the 4 week study compared to those receiving the placebo.
Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: Body inflammatory markers
Attribute: Comparison of pre- and post-study blood levels of IL-1-β

3.

Subjects randomly assigned to the ALCAT treatment group will have lower IL-6 at the
end of the 4 week study compared to those receiving the placebo.
Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
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Control: Participants will receive a placebo food elimination plan
Dependent Variable: Body inflammatory markers
Attribute: Comparison of pre- and post-study blood levels of IL-6
4.

Subjects randomly assigned to the ALCAT treatment group will have lower MPO at the
end of the 4 week study compared to those receiving the placebo.
Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: Body inflammatory markers
Attribute: Comparison of pre- and post-study blood levels of MPO

5.

Subjects randomly assigned to the ALCAT treatment group will have lower SAA at the
end of the 4 week study compared to those receiving the placebo.
Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: Body inflammatory markers
Attribute: Comparison of pre- and post-study blood levels of SAA

6.

Subjects randomly assigned to the ALCAT treatment group will have lower TNF-α at the
end of the 4 week study compared to those receiving the placebo.
Independent Variable: Food Elimination Plan
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Attributes: Elimination of foods decided by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: Body inflammatory markers
Attribute: Comparison of pre- and post-study blood levels of TNF-α
7.

Subjects randomly assigned to the ALCAT treatment group will have lower FM and
higher LBM at the end of the study compared to the placebo group.
Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: FM and LBM
Attributes: FM and LBM assessed using bioelectrical impedance (Biospace)

8.

Subjects randomly assigned to the ALCAT treatment group will have lower fat percent at
the end of the study compared to the placebo group.
Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: Fat percent
Attributes: Fat percent assessed using bioelectrical impedance (Biospace)

9.

Subjects randomly assigned to the ALCAT treatment group will have a lower abdominal
WC at the end of the study compared to the placebo group.
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Independent Variable: Food Elimination Plan
Attributes: Elimination of foods determined by ALCAT based on individual blood
tests; varies per person
Control: Participants will receive a placebo food elimination plan
Dependent Variable: Abdominal WC
Attributes: Abdominal WC measured with a cloth tape anteriorly halfway between
the lowest lateral portion of the rib cage and the iliac crest.

CHAPTER 2

REVIEW OF LITERATURE

Introduction
Obesity rates have more than doubled from 13% to 35.7% in the United States and
worldwide over the last two decades (1, 13). It is predicted by World Health Organization
(WHO) that 2.5 billion people worldwide will be overweight with a body mass index (BMI)
greater than 25 and 700 million people will be obese with a BMI over 30 by the year 2015 (14).
Obesity is a major health concern since obesity is strongly linked to inflammation and a number
of inflammatory related disorders, such as coronary heart disease, insulin resistance, type 2
diabetes and non-alcoholic fatty liver disease (15,16).
Numerous studies have shown that as visceral adipose tissue increases, pro-inflammatory
cytokines such as CRP, IL-1-β, IL-6, MPO, and TNF-α also increase. The cascade of proinflammatory cytokines favors insulin resistance leading to more weight gain as fat. It becomes
a repetitive cycle of increased inflammation and more deposition as fat (6-8, 15, 16, 18).
Furthermore, the multitude of cytokines released in relation to obesity can change from
protecting the body to leading to inflammatory diseases (2,4).The presence of low-grade
inflammation has been positively associated with adiposity (19). Abdominal weight gain
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is a standard indicator of adipose tissue accumulation (6,16) which promotes low-grade chronic
inflammation (15-16). Adipose tissue is an active secretory organ that sends out and responds to
signals that control appetite, energy expenditure, bone metabolism, endocrine and reproductive
systems, insulin sensitivity, as well as immunity and inflammation (6, 16).
Inflammation is a protective response of the immune system to harmful stimuli, such as
infection, acute illness, trauma, toxins, many chronic diseases and physical stress (2). Chronic or
prolonged inflammation occurs when the body continues to produce inflammatory mediators
past the acute response phase (2). Chronic inflammation is characterized by the increased
presence of macrophages in the injured tissue, which leads to tissue damage and healing the
tissue during the inflammatory process (3). Chronic inflammation can lead to systemic
inflammation which can negatively affect many functions of the body, such as digestion and
absorption. Inflammatory conditions trigger the immune system to release eicosanoids (n-6
eicosanoids, leukotriene B4, prostaglandin E2) and cytokines (CRP, IL-1-β, IL-6, MPO, TNF-α),
which mobilize nutrients needed in the inflammatory process (2,20). As a result, cytokines,
especially IL-1-β, IL-6, TNF-α, impact whole body metabolism, body composition and
nutritional status (2).
The link between poor nutritional status and impaired immune function has been firmly
established (2,20). However, research regarding diet quality, inflammatory markers, and its
subsequent effect on immunity is minimal (21,22). A study was conducted to look at the
association between healthy eating patterns and immunity and inflammation in overweight or
obese menopausal women (21). Boynton et al, found limited evidence that healthy eating habits
in postmenopausal women enhanced immune function and decreased inflammation (21). The
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study showed that higher diet quality was associated with lower levels of serum CRP or SAA
(21). Furthermore, diet quality has been linked to inflammatory markers, specifically CRP and
SAA, where the association is largely affected by adiposity. Consumption of a healthier diet
potentially leads to a decrease in adipose tissue, which may result in decreased levels of
inflammatory markers (21,22). Further research supports the relationship between diet quality
and inflammation. In a systematic literature review, foods associated with increased serum levels
of CRP and IL-6 included red meats, processed meats, low-fiber foods or refined grains, and
alcohol (22). Inversely, consumption of foods such as fruits, vegetables, and whole grains
showed decreased serum levels of CRP and IL-6 in the study participants (22). Additionally, the
Framingham Heart Study reported that as BMI, visceral adipose tissue, subcutaneous tissue, and
WC increased serum levels of CRP and IL-6 also increased (17).
Diet and exercise are known to reduce inflammation (9,19). It is well known that
consuming a diet rich in fruits and vegetables, low in refined starches, sugar, saturated and transfatty acids reduces the level of inflammatory cytokines. Additionally, a decrease in CRP, IL-6
and TNF-α has been found with diet-induced weight loss (4,20). A study investigated the
relationship between inflammation and food digestion and discovered that impairments in
intestinal structure, digestive and absorptive function, and barrier function are a result of
inflammation originating in the intestine or distant locations (23). Currently, it is unknown what
effect the removal of food intolerances from the diet will have on the body. It is suspected that
systemic inflammation, as measured through CRP, IL-1β, IL-6, MPO and TNF-α, will decrease,
thereby, reducing insulin resistance and promoting weight loss.
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The level of inflammation can be exacerbated by one or more existing food intolerances.
If food intolerances are present, they will stimulates the fight or flight response and increases
food cravings. This in turn, makes one eat a larger serving of that food which will lead to more
inflammation. Continued exposure to allergens provides constant pro-inflammatory stimuli
which increase the body’s inflammatory response resulting in tissue damage and loss of barrier
function thus leading to systemic inflammation (4). Joint pain is a common result of systemic
inflammation. TNF-α and IL-1β are believed to promote cartilage damage and CRP has been
shown to be elevated in patients with osteoarthritis. Therefore, cartilage breakdown in
osteoarthritis may be worsened by inflammation (20). Activated macrophages at the site of
inflamed cartilage secrete TNF-α and IL-1, which lead to the loss of the integrity of the cartilage
in the joints (4).

Food Intolerances
Food allergy by definition is an abnormal immunologic response to a food that occurs in
a susceptible individual (24). Allergic reactions usually occur immediately and every time the
food is consumed, even in small amounts. Food allergy reactions are facilitated by
immunoglobulin E (IgE) antibody (24). Unlike food allergy, food intolerance refers to a variety
of non-immunologic reactions, which are mediated by the innate branch of the immune system,
occurring after consumption of a particular food (24). These abnormal physiologic responses
may be unpredictable due to a gamut of reasons such as intrinsic properties of the food or to
biological characteristics of the individual consuming the food (24). These symptoms may not be
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reproducible, may be delayed, and often depend on the quantity of the food consumed (24,25).
Food intolerances to foods have been reported to cause low-grade inflammation throughout the
body (14). For example, consumption of fried, fatty, junk foods and sweets have been associated
with increased systemic inflammation and elevated CRP levels (26).
Prevalence of Food Intolerances in the US
The prevalence of food allergy appears to be on the rise in Westernized cultures (24). For
example, peanut sensitization tripled and reported peanut allergy in children doubled over only a
five-year period in both the United States and United Kingdom (24). Although evidence
indicates an increasing prevalence, a discrepancy between patient- perceived and physicianconfirmed food allergy exists. The prevalence of food allergy, with an immediate immunological
response, is highest in infants and toddlers. Cow’s milk allergy is experienced by 2.5% of
infants, and up to 8% of children under 3 years of age have allergy to a limited number of foods,
mainly cow’s milk, egg, soy, peanut, wheat, fish, shellfish, or tree nuts (24). The prevalence of
food allergy decreases slightly with age, affecting almost 4% of the general population (24,25).
In contrast, food intolerance is more common than food allergies but usually go
undiagnosed due to delayed symptomology or improper format of testing. Research has shown
that upwards of 70-80% of the US population reports having symptoms associated with food
intolerances (25). Yet, these individuals are not able to be diagnosed with a food allergy due to
the lack of IgE response when tested (25).
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Cause of Food Intolerances
Research has found that some primary reasons for food intolerances are an imbalance of
fatty acids, chemicals in foods that the liver cannot break down, impaired gut function, and
inherited enzyme deficiencies or metabolic disorder (10,24). It is important to note that inherited
enzyme deficiencies or metabolic disorders that cause intolerance to food will not change
secondary to genetics but if properly addressed, moderate quantities of the problematic food may
be tolerated (10,24). However, the remaining aforementioned factors have been linked to
unhealthy food consumption where the avoidance of such food results in weight normalization,
attenuation of inflammation and reduction of other inflammation-based health issues (10).
Specifically, fatty acid imbalances may result from the overabundance of corn and soy in the diet
which contains high omega-6 fatty acids. These omega-6 fatty acids promote high arachidonic
acid levels which in turn promote chronic, pro-inflammatory cytokine production (10).
Additionally, natural or synthetic chemicals in a variety of foods in today’s diet are difficult for
the liver to effectively detoxify and thus activate the immune system (10). For example,
salicylates occur naturally in many fruits and vegetables, and can induce a pharmacologically
mediated adverse reaction in susceptible individuals. Some examples of food-related factors
responsible for non-immunologic reactions include improperly stored fish that became
contaminated with histamine, or the presence of tyramine in aged cheese, alcoholic beverages,
and cured meats (24). Furthermore, decreased gut function occurs when the gut membrane is
compromised. When this natural barrier is damaged, the immune system is called into action as
well (10).
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Intolerances to foods are mediated by the innate branch of the immune system and thus
follow a different pathway than pathogens (10). Food intolerances symptoms are dose-related,
chronic and delayed (10). Inflammation, toxic free radicals, and immune chemicals are produced
as a result of food intolerances (10). These products may lead to high risk of metabolic, chronic
and degenerative diseases (10).

Symptoms of Food Intolerances
Cellular reactions to food can cause inflammatory reactions which have been linked to a
number of chronic health problems such as obesity, diabetes, migraines, and asthma in addition
to skin, heart, joint, and digestive disorders (14,20,25). The extra-intestinal manifestations and
other reactions to foods, such as bloating and swelling in the hands, feet, ankles, abdomen, chin
and around the eyes, may not display immediate symptoms but can present many hours later.
Inflammation associated with food sensitivities can lead to weight gain. Fluid retention caused
by inflammation and the release of certain hormones and cytokines, such as IL-6 and TNF-α, are
the major causes of the weight gain (14,25)
Poor digestion, malabsorption of nutrients, and thus reduced nutritional status are also
symptoms of food intolerances. Research shows that impaired gut function such as digestion,
absorption, and barrier function, result from inflammation (12,23). Intestinal inflammation can
impair both digestion and absorption within the inflamed area as well as surrounding intestinal
areas which makes proper digestion and adequate nutrition challenging (12,23). For example, in
inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, the brush border
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activity is reduced, the transit time of food and nutrients is decreased so contents travel through
the intestinal tract quicker, and the absorptive mucosa cells may be damaged (12). Celiac disease
is a condition where eating gluten triggers an immune response in the small intestine, resulting in
inflammation of the mucosa. As a result, the villi become atrophied and flattened, thus impairing
digestion and absorption (12). Diarrhea, abdominal pain, malabsorption, and weight loss are
symptoms of Celiac disease (12). Some extra-intestinal manifestations of Celiac disease include
skin rashes, muscle and joint pain, as well as fertility issues in females (12). Additionally,
individuals with food intolerances tend to have poor food intake when not feeling well which
exacerbates poor digestion and malabsorption of nutrients (12).

Inflammatory Markers
There are a number of inflammatory cytokines in the human body. Each cytokine serves
a particular purpose during the inflammation process. In a number of studies, the increased
presence of inflammatory cytokines has also been associated with obesity, where these cytokines
produced and released by the white adipose tissue (WAT) are responsible for the chronic
inflammatory state of obesity (16,27). In healthy individuals, adipocytes produce proinflammatory cytokines such as IL-6 and TNF-α (2,6,16,20, 28). IL-6 then stimulates the
synthesis of CRP in the liver, all of which is increased with obesity (2,17,28i). Rexrode et al,
found a significant and positive association between IL-6 and CRP and all levels of BMI, and
WC (29). Another study found that BMI and percent body fat were significant predictors of
increased serum levels of IL-6 and CRP, whereas no association between adiposity and TNF-α
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was shown (28). Ma et al, from Zhejiang University in Hangzhou, China, reported that several
types of obesity were associated with chronic low-grade inflammation (3). Research shows that
isolation of one cytokine in the pathophysiology is unlikely and that a compilation of cytokines
predict disease (17). Therefore, in the present study multiple inflammatory markers were
investigated: CRP, IL-1-β, IL-6, MPO, SAA, and TNF-α.

C-Reactive Protein
CRP is a protein that is synthesized in the liver (3,30) and in healthy individuals its level
is less than 2mg/L in healthy individuals (15). Therefore, elevated levels of CRP can be used as a
strong biomarker of low-grade inflammation (3,15,18,30). IL-6 has been found to be strongly
correlated with the synthesis of CRP in response to an increase in visceral adipose tissue.
(26,30). Research shows a positive correlation between circulating CRP levels and BMI
(15,18,29-31). Moreover, elevated levels of CRP are associated with increased risk of
atherosclerotic diseases, stroke, cardiovascular disease and diabetes (15,29). Studies have shown
that elderly individuals commonly have elevated serum levels of TNF-α and CRP (20). A study
looking at the relationship between adiposity with CRP and IL-6 found that higher CRP and IL-6
levels were observed as BMI levels increased (29). Another study by Khaodhiar et al., concurs
with this study and reported almost identical findings (18). Interestingly, Khaodhiar et al., found
the association between CRP and BMI to be greater for men as opposed to women due to a
higher amount of visceral adipose tissue in males (18). In contrast, Rexrode et al., reported this
association stronger in women than men (29). It was also found that weight loss in obese women
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resulted in decreased levels of CRP, thus potentially decreasing their risk of cardiovascular
disease and diabetes (29). These findings were further supported by research showing that a
healthy diet and weight loss were found to reduce CRP levels (30). Additionally, a longitudinal
study conducted to examine the effect of BMI on CRP found that as BMI and body mass
remained stable, so did CRP levels which coincides with previous research that BMI is positively
associated with CRP. (31). Overall, a loss in weight and a decrease in BMI has been shown to
decrease levels of CRP in both males and females.

Interleukin-1-Beta
IL-1-β is an adipokine that is synthesized in human white adipose tissue, along with
TNF-α and IL-6, and exhibits pro-inflammatory properties (20,27). IL-1-β, TNF-α and IL-6 are
often used as markers to assess inflammation (32). IL-1-β plays a role in the regulation of SAA
during the inflammatory process (33). IL-1-β initiates the production of cyclooxygenase-2
(COX-2), an enzyme that is abundant in activated macrophages and other cells that are seen at
the site of inflammation. COX-2 has been shown to be abundant in various carcinomas and to
have a central role in tumorigenesis. Thus, IL-1-β is most often associated with pain caused by
inflammation.
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Interleukin-6
IL-6 is a pro-inflammatory cytokine that participates in both trauma-related acute phase
response and stress-related inflammatory response (6). A general systemic inflammation can
occur when the stress is chronic (6). IL-6 is synthesized in human adipose tissue and plasma
concentrations increase with obesity (3,7) where expression of IL-6 is higher in visceral than
peripheral adipocytes (7,20). IL-6 obtains pro-inflammatory activity either by itself or by
increasing levels of IL-1-β and TNF-α (3). Additionally, IL-6 stimulates the liver production of
CRP (3). IL-6 is an adipokine that is synthesized in human white adipose tissue, along with IL-1β and TNF-α, and exhibits pro-inflammatory properties (20,27). Obesity is related to increased
circulating levels of these cytokines (17,20,27,34). In normal weight women with high a high
amount of adipose tissue, both IL-6 and TNF-α concentrations were associated with fat mass
distribution (27). Higher IL-6 levels were observed with higher BMI levels; lower IL-6 levels
were reported with a decrease of BMI (18,29). Elevated IL-6 levels are associated with
subsequent heart attacks and diabetes (29).

Myeloperoxidase
MPO is a heme protein that constitutes the major component of neutrophils. (32).
Therefore, MPO enzyme activity is used to measure neutrophil function (32). Plasma MPO is
involved in the releases reactive oxygen species (ROS) and thus may impart damage to proteins,
carbohydrates, lipids, and nucleic acids that serve as biological structures (32). This destruction
may exacerbate the body’s inflammatory response and potentially result in sepsis (32). During a
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state of oxidative stress, increased amounts of neutrophil surround the affected area and release
MPO into the bloodstream. Therefore, plasma levels of MPO enzyme activity serves as a
biomarker of inflammation, especially when sepsis is present (32).

Serum Amyloid A
SAA is an acute phase protein from the apolipoprotein family associated with high
density lipoproteins (HDL) in the blood. SAA is produced in the liver and regulated by IL-1, IL6, and TNF-α in response to inflammatory stimuli, such as stress, injury, infection, or trauma
(33). Due to the quick response of SAA, similar to CRP, it is a sensitive biomarker for the acute
inflammatory state (21,33). SAA, along with IL-6 and TNF-α, are known to be elevated in obese
individuals as these inflammatory markers are expressed in adipose tissue (33). Research shows
that elevated systemic SAA concentrations are associated with impaired glucose tolerance and
type 2 diabetes mellitus, independent of established type 2 diabetes risk factors, BMI, waist-tohip ratio, and body fat mass index (33). Research suggests that elevated SAA levels are not the
cause of diabetes but a result of the pre-diabetes process (33). Limited research found that
healthy eating patterns may contribute to decreased circulating SAA levels such that
consumption of a healthier diet potentially leads to a decrease in adipose tissue, which may result
in decreased levels of inflammatory markers, specifically CRP and SAA (21).
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Tumor Necrosis Factor-alpha
TNF-α is an adipokine that is synthesized in human white adipose tissue, along with IL1-β and IL-6, and exhibits pro-inflammatory properties (6,27). TNF-α in adipose tissue acts
locally but can promote insulin resistance peripherally (7,20,34). Studies have shown that elderly
individuals commonly have elevated serum levels of TNF-α and CRP (20). TNF-α affects lipid
metabolism and is correlated with high triglyceride levels and low HDL cholesterol levels (20).
In a study by DeLany, TNF-α was reported to elicit a chronic inflammatory state thus
contributing to the onset of cancer, heart disease, arthritis, and many other health problems (6).
This may be due to the fact that TNF-α stimulate the synthesis of IL-6, which in turn stimulates
the synthesis of CRP and thus contributes to the maintenance of chronic low-grade systemic
inflammation, especially with the presence of obesity (15). Another study found that as BMI
increases up to a BMI of 40, TNF-α also increases; above 40 there were no further increases of
TNF-α (18).

Downside of Systemic Inflammation
Inflammation can cause alterations in gastrointestinal functions that last long after the
acute inflammation has been resolved (20). There are nutritional consequences of cytokinemodulated actions as a result of chronic inflammation. The brain, endocrine system, liver,
muscles, blood and gastrointestinal tract are target areas of cytokine-modulated behavior. The
brain will experience a sickness syndrome that includes fatigue, apathy, cognitive dysfunction,
anorexia, and sleepiness resulting in weight loss due to decreased food intake (2). The endocrine
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system displays a euthyroid sickness, anorexia and an increase in the metabolic rate which
results in muscle wasting due to decreased food intake (2). Increased synthesis of positive acute
phase proteins, decreased synthesis of negative acute phase proteins, increased fatty acid
synthesis, increased lipolysis and decreased lipoprotein lipase are all seen in the liver which
results in increased edema and hypertriglyceridemia. Increased insulin resistance is observed in
the muscles and results in hyperglycemia (2). In the blood, decreased red blood cells production
occurs as well as a redistribution of albumin, pre-albumin and iron which results in anemia and
increased edema (2). However, the increase in white blood cells, primarily leukocytes, results in
activated inflammatory mediators which can interfere with lipolysis and thus inhibit weight loss
(10). Lastly, in the gastrointestinal tract, the rate of protein breakdown increases, the gastric
secretions decrease, gastrointestinal mobility slow down, and emptying time increases, this
combination results in decreased protein reserves (2).

Body Composition
Body composition is utilized in tangent with other assessment tools to provide a precise
depiction of an individual’s overall health (2). Anthropometric methods used to assess body
composition are based on the theory that the body is made up of two chemically distinct sections;
fat and fat-free mass (35). Areas of focus in this study are fat mass, fat percent, lean body mass,
and WC. BMI was found to be independently associated with IL-6 and CRP and unfitoverweight participants had significantly higher IL-6 and CRP (19). Studies show that dietinduced weight loss reduces serum concentrations of CRP, IL-6, and TNF-α (15,20).
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Fat-Free Mass
FFM consists of muscle (skeletal and non-skeletal), soft lean tissues, and the skeleton and
is a mixture of water, protein, and minerals with muscle acting as the major protein source (35).
FFM is a measurement used to assess body fatness or overweightness and obesity. In fact, FFM
is often preferred over BMI since it is a more accurate assessment tool of LBM (36). FFM is
expressed in kilograms (kg) (36).

Percent Body Fat
Body fat (BF) is the primary way the body stores energy and is sensitive to severe
malnutrition (35). Percent BF is measurement used to assess body fatness in regards to
overweightness and obesity (36). Often times, percent BF is preferred over BMI since it is a
more accurate assessment tool of adiposity (36). Percent BF is expresses as a percentage (%)
(36).
In a study by Wong et al., the levels of IL-6 and CRP were measured with weight loss
and again with a decrease in percentage of body fat; the results were similar (17). The results
showed that as percent BF and weight decreased both IL-6 and CRP declined (17).
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Lean Body Mass
LBM is a component of body composition, calculated by subtracting body fat weight
from the total body weight. This is calculated to distinguish between body fat mass and LBM
(36). LBM has typically been used for prescribing proper levels of medications and for assessing
metabolic disorders. (36). Research shows that LBM is superior to total body weight as a clinical
measure as body fat is less relevant for metabolism (36). LBM is expressed in kg (36).

Waist Circumference
WC measurement is an established assessment of abdominal visceral adipose tissue
(6,12). WC is found by measuring the distance around the smallest area below the rib cage and
above the umbilicus with the use of a non-stretchable tape measure (2,12). In obese individuals,
the waistline may be more difficult to locate, therefore, finding the point halfway between the
inferior surface of the ribs and the top of the iliac crest may be the best location for WC
measurement on obese individuals (6). Measurements over 35 inches for women and over 40
inches for men are considered independent risk factors for disease (2,6). However, these
parameters may not be as useful for individuals with a BMI of 35 or more (2).

Bioelectrical Impedance Analysis
Bioelectrical Impedance Analysis (BIA) is a technique to analyze body composition and
is based on the principle that, relative to water, lean tissue has a greater electrical conductivity
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and lower impedance than fatty tissue due to its electrolyte content (2). BIA is a safe, noninvasive, portable and rapid method to measure body composition, particularly LBM (2,12). BIA
is a reliable method for large populations (12). For the best results, the individual should be wellhydrated, abstain from alcohol, caffeine, or diuretics in the last 24 hours and abstain from
exercise in the last 4 to 6 hours (2). However, fever, electrolyte imbalance, and extreme obesity
may affect the reliability of the measurements (2).

ALCAT
History and Purpose
The ALCAT test utilizes a food sensitivity blood test to identify potential cellular allergic
reactions for over 350 foods, chemicals and herbs (2,11,25). ALCAT is useful is identifying food
intolerances in cell-mediated or delayed inflammatory reactions. These inflammatory reactions
are linked to chronic health problems like obesity and diabetes, as well as skin, heart, joint, and
digestive disorders (25). It is strongly recommended that the ALCAT test be followed up with a
subject-specific elimination diet and clinical observation (2). ALCAT diets require the
elimination of intolerant foods and thus should decrease appetite, reduce systemic inflammation,
enable weight-loss and improve body composition (11,14).
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ALCAT Testing
The ALCAT test measures the effect of the food on the cells in the innate immune system
to determine if a food intolerance is present (10). Specifically, ALCAT is an indirect
measurement of the presence of prostaglandins, cytokines, and leukotrienes released from the
degranulation of leukocytes in the presence of an allergen and measures the change of leukocyte
via an automated computer analysis, called the ROBOCat II (2,14). The degree of food
intolerance is determined by comparing the size and volume of the leukocytes post reaction to
the baseline leukocyte sample given by the individual (14). Based on the level of leukocyte
reactivity when tested, the foods will be labeled as acceptable foods or as a mild, moderate, or
severe intolerance (25). According to Kaats, et al., the ALCAT test was found to be an effective
test that offers individualization to the patient being tested (11). Furthermore, blind studies have
revealed that ALCAT is the most accurate test to support a strong correlation between clinical
symptoms and food (10).

Justification for Food Elimination
The purpose of a food elimination diet is to remove the suspected food(s) from the diet
for specific time period, usually 4-12 weeks, and followed by a reintroduction phase where the
food is brought back into the diet. Food elimination diets are designed on an individual basis (2)
and in the case of this study the elimination diets for the ALCAT group were based on the
ALCAT test results. Since food intolerance results from activation of the innate immune system,

26

the avoidance of the problematic food(s) will result in improved gut integrity and healed gut
barrier, increased liver detoxification, and better overall nutritional status (10).
Successful weight loss and effective healthy eating patterns rely heavily on proper
identification of factors related to food intolerance (10). In a double blind study by Akmal et al.,
an 83.4% correlation was determined between ALCAT test results and a statistically significant
number of patients exhibiting food sensitivity related extra-intestinal symptoms, such as
migraines, irritable bowel syndrome, eczema and other conditions that are often observed as comorbidities in obese patients (14). Kaats et al., found that the ALCAT testing and corresponding
diet plan, used by the ALCAT group and compared to the control group showed positive results,
such as an improved body composition and a decrease in self-reported disease symptoms (11).
According to the Baylor University study, evidence supports the effectiveness of ALCAT testing
in improving BMI and/or weight when the participants followed the recommended elimination
diet based on ALCAT testing (14). For example, in the Baylor University study, it was shown
that 98% of the participants, following the elimination diets based on ALCAT testing, lost
weight, which was primarily from fat loss, and/or saw improvements in overall body
composition (14). Additionally, these participants reported improvements in physical
performance, sense of well-being, abdominal bloating and digestive issues (14).

Conclusion
Research has shown that obesity is a major cause of systemic inflammation (30).
Furthermore, studies have shown that diet quality, not solely quantity of intake, plays an
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important role in potential inflammation caused by foods (11,14,30). Additionally, it is important
to determine if dietary patterns alone or in combination with increased adiposity have the
greatest effect on systemic inflammation and body composition. Food intolerance is more
common than food allergies. Research has shown that upwards of 70-80% of the US population
reports having food intolerance experiences (25). Yet, intolerances to foods usually go
undiagnosed due to delayed symptomology or improper format of testing. Hence, the purpose of
this study was to examine what effect food elimination had on body composition and on overall
body inflammatory markers using ALCAT testing.

CHAPTER 3

METHODS

Participants
One hundred forty-six participants were selected to take part in this study. Participants
were recruited by posting an advertisement in the local paper, by posting flyers on campus or in
fitness centers within a 50 mile radius of Northern Illinois University (NIU) DeKalb campus
(Appendix A), and via social media such as Facebook and LinkedIn. Those individuals meeting
the Disease Symptom Inventory (DSI) criteria of having at least two or more of the symptoms
listed and rating them as “somewhat severe effect” were selected for the study. Participants
completed a disease symptom inventory (Appendix B), a medical survey questionnaire
(Appendix C), and an ALCAT screening form (Appendix D). Participants kept a three-day food
record including two weekdays and one weekend day (Appendix E), kept an exercise log for one
week (Appendix F), and had 25 mL of blood taken to assess food intolerances at baseline and
levels of CRP, IL-1-β, IL-6, MPO, SAA, and TNF-α, at baseline. Participants had an additional
3.5 mL of blood taken on the last day of the 4-week long study to retest levels of CRP, IL-1-β,
IL-6, MPO, SAA, and TNF-α. Those individuals who were pregnant, had hemophilia, or were
under the age of 18 or over the age of 65 were ineligible to participate in the study.
All participants were informed of the risks and benefits associated with this study and
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were required to give written consent to participate (Appendix G) in accordance with the study
procedures approved by Northern Illinois University Institutional Review Board (Appendix H)
and the Institutional Biosafety Committee (Appendix I), prior to enrollment in this study. All
participants were debriefed at the end of the study (Appendix J).

Experimental Design
This was a randomly assigned pre- and post-test double blind experimental study.
Participants were assigned to groups using a random number chart. On day one and the last day
of the four-week long study, subjects reported to the nutrition laboratory at NIU to have
anthropometrics and blood samples taken. The blood samples determined ALCAT results for
200 foods (only on day one), 50 functional foods and medicinal herbs, and 50 chemicals and
molds and inflammatory marker levels (both pre and post study).
All participants were assigned and counseled on an individualized elimination diet plan
based on ALCAT testing (n=73) or sham list of foods (n=73). This diet plan was followed for
four consecutive weeks. An exercise log was completed to control for extraneous body
composition changes.

Data Collection
The participants completed a three-day food record (two weekdays and one weekend
day), a weekly exercise log, complete the disease symptom inventory and medical symptom
inventory, had their height, weight, body fat percentage, lean body mass and abdominal WC
measured at baseline and at the end of the month long study (Appendix K).
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Anthropometry
Participants reported to the nutrition laboratory at NIU. All body measurements were
taken with participants in light weight clothing and bare feet. Height was measured using a wallmounted stadiometer (Ayrton S-100 Prior Lake, MN). Weight, FM, percent fat, and FFM were
assessed using bioelectrical impedance (InBody 520, Biospace Inc. Los Angeles, CA).
BMI, using the standard equation (kilogram per meter squared), was calculated by the
InBody 520.
Abdominal WC was measured with a cloth tape anteriorly halfway between the lowest
lateral portion of the ribcage and the iliac crest.

Blood Samples
In addition to anthropometric data collection, participants had their blood drawn in the
Nutrition Laboratory (308A Wirtz Hall) by trained phlebotomists while wearing gloves and a lab
coat. After the subjects arm site was prepared by cleaning with an alcohol swab, either a 22
gauge needle or a 21 or 23 gauge butterfly was placed in an arm vein in order to obtain blood
samples. After the blood was taken, the venipuncture site was covered with gauze and slight
pressure was applied to the site. The site was then covered with a band-Aid. The needles and
gauze products covered with blood were disposed of in clearly labeled sharp containers which
were available in the Nutrition Laboratory in 308A Wirtz Hall. .
Four blue top vials (4.5 mL each) containing 3.8 % buffered sodium citrate and one gold
top serum separator (SST) was obtained. The Blue top blood sample assessed food sensitivities
using ALCAT and the gold top was used to assess inflammatory markers CRP, IL-6, IL-1 β,
SAA, MPO and TNF-α. The tubes were labeled with the participant's name, time and date of
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collection. Blue top vials were immediately inverted several times to ensure proper mixing. The
gold top vial was centrifuged (Compact II Centrifuge made by Clay-Adams, Beckton Dickinson
Company) at 3000 RPM for 15 minutes to separate the plasma cells from the serum. All vials
were placed into the slots of the foam sleeves which were then be placed into a biohazard
specimen bag. The requisition form was placed in the front pouch of the specimen bag. The strip
covering the blue adhesive was removed and the bio-hazard specimen bag was sealed. The
specimen bag with vials and requisition were placed into a silver insulated bag and the bag was
sealed. The insulated bag was placed in the box provided by ALCAT. The specimen were
placed into the pre-paid UPS Laboratory Pak and sealed tightly. The specimens were transported
to the local UPS store and sent overnight to Cell Science Systems 852 South Military Trail
(ALCAT headquarters) in Deerfield Beach, FL.

Diet Analysis
Diet analysis was performed using a three-day food log that the participants in this study
completed. Participants were instructed on how to approximate serving sizes and how to identify
ingredients in their food so that the most accurate analysis can occur. It was explained that the
more accurate the log, the more accurate the diet analysis will be. The purpose of this was to
determine if the participants were following the recommended elimination diet plan. Diets were
to be analyzed to the nearest total calorie and nearest ½ gram of protein. NutritionCalc Plus
(McGraw-Hill Companies, Columbus, OH, 2009) was utilized for the data entry and analysis of
the three-day food log. A graduate nutrition student who had training with the system entered the
data.
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Statistical Analysis
Descriptive measures were analyzed using a one-way analysis of variance
(ANOVA). Within and between group differences in body composition and inflammatory
markers at day one and at the end of the four-week elimination diet were analyzed using repeated
measures ANOVA. Significant main and interaction effects were analyzed using the Bonferonni
post-hoc method for multiple comparisons. This data was expressed as m + SD. Univariate
analysis of variance was utilized to examine body composition. Three response variables (lean
body mass, percentage BF, and WC) were analyzed with univariate regression adjusted by age,
gender, and baseline outcomes. This data was expressed as F value and significance (p) level.
Statistical significance for all data analysis was accepted at the p<0.05 level of confidence. Data
was analyzed by using the Statistical Package for Social Sciences (SPSS) for Windows (Version
21.0, 2013, SPSS, Inc, Chicago, IL)

CHAPTER 4

RESULTS

Research Methodology
The purpose of this study was to determine whether the elimination of foods determined
to cause an inflammatory response would lead to a decrease of inflammation and an
improvement of body composition. In this double blind study, subjects were randomly assigned
by Cell Science Systems to either the control group (n=59) in which the participants received a
placebo elimination diet or the treatment group (n=72) in which the participants were given an
accurate list of foods they had severe and moderate reactions to, based on ALCAT testing. Those
foods were eliminated for 4 weeks.

Participants
One hundred forty-six participants were enrolled in the study and completed the initial
data collection process. The participants were randomly assigned to the treatment or control
group. Fifteen participants were withdrawn from the study due to lack of response to a
scheduling email for the follow-up appointment. One hundred thirty-one participants, control
group (n=72) and treatment group (n=59), completed all phases of the study.
There were no significant differences in age, BMI, percentage BF, height, WC, weight,
and medical symptom questionnaire scores between participants in the
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treatment or control group at the start of the study. Descriptive data is shown in Table 1 and
Figure 1.

Table 1: Physical Characteristics of Subjects
Variable

Group

Data

Group Totals

Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment

59
72
34.85 + 11.52
34.79 + 12.91
27.15 + 6.56
27.45 + 5.93
31.35 + 10.71
31.59 + 9.51
168.33 + 8.28
167.51 + 11.69
88.22 + 13.20
90.69 + 17.16
77.48 + 18.66
78.76 + 20.58
56.20 + 31.22
58.46 + 32.49

Age (years)
BMI
Body Fat %
Height (cm)
Waist Circumference (in)
Weight (kg)
Medical Questionnaire Day 1

35
180
160
140
120
100
Control

80

Treatment

60
40
20
0
Age
(years)

BMI

Body Fat
%

Height
(cm)

WC (in)

Weight MQ, Day 1
(kg)

Figure 1: Physical Characteristics of Subjects

Inflammatory Markers
CRP, MPO, SAA, TNF-α
Four inflammatory markers, CRP, MPO, SAA and TNF-α, showed a significant decrease
at the end of the four-week study. There was a significant decrease in CRP levels for both the
treatment group (p=0.0024) as well as for the control group (p=0.0259) during the study. (2.44 +
3.83to 1.09 + 1.35 and 2.54 + 4.43 to 1.18 + 1.24, respectively). Similarly, there was a
significant decrease in MPO levels for both the treatment group (p<0.0001) as well as for the
control group (p<0.0001) during the study (302.78 + 245.85 to 181.06 + 134.39 and 352.00 +
288.25 to 167.81 + 112.00, respectively). Likewise, there was a significant decrease in TNF-α
levels for both the treatment group (p<0.0001) as well as for the control group (p<0.0009) during
the study. (0.81 + 0.50 to 0.67 + 0.32 and 0.74 + 0.14 to 0.65 + 0.14, respectively). However,
there was a significant decrease in SAA levels for the treatment group (p=0.0017) but not for the
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control group (p=0.0761) during the study. (51.08 + 46.96 to 30.92 + 37.91 and 42.60 + 40.68 to
31.55 + 35.10, respectively). Full results can be found in Table 2 and Figures 2-4.

IL-1-β and IL-6
There were no significant decreases in IL-1-β or IL-6 levels for either the treatment or the
control group during the 4 week study.

Comparison of Changes in Inflammatory Markers
When analyzing the levels of inflammatory markers at day one and day thirty for control
and treatment groups, mixed results were found. There was a significant decrease in CRP, MPO,
TNF-a in both the control (p=0.0259, p<0.001, p=0.009, respectively) and treatment groups
(p=0.0024, p<0.001, p<0.001, respectively). There was a significant decrease in SAA for the
treatment group (p=0.0017) but not the control group. There was no significant decrease in IL-1β or IL-6 noted for either the control or the treatment group. See Figure 4.
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Table 2: Inflammatory Marker Changes over the Course of the 4-Week Study
Variable
CRP

Group
Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Control
Treatment

IL-1-β
IL-6
MPO
SAA
TNF-α

Day 1
2.54 + 4.43
2.44 + 3.83
0.46 + 0.36
0.63+ 1.76
3.34 + 1.03
3.62+ 2.59
352.00 + 288.25
302.78 + 245.85
42.60 + 40.68
51.08 + 46.96
0.74 + 0.14
0.81 + 0.50

Day 30
1.18 + 1.24
1.09 + 1.35
0.40 + 0.47
0.45 + 0.98
3.25 + 0.68
3.60 + 1.51
167.81 + 112.00
181.06 + 134.39
31.55 + 35.10
30.92 + 37.91
0.65 + 0.14
0.67 + 0.32

Comparison - Day1 & Day 30
1.36 + 4.57*
1.35 + 3.63*
0.06 + 0.60
0.19 + 0.81
0.08 + 0.62
0.02 + 1.87
184.2 +278.4*
121.7 +221.3*
11.05 + 47.02
20.15 + 52.37*
0.09 + 0.19*
0.14 + 0.22*

*indicates p<0.05

400
350
300
250
Control

200

Treatment

150
100
50
0
CRP

IL-1-β

IL-6

MPO

SAA

TNF-α

Figure 2: Inflammatory Markers at Day One of the 4-Week Study
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Figure 3: Inflammatory Markers at Day Thirty of the 4-Week Study
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Figure 4: Comparison of Change in Inflammatory Markers at the End of the 4-Week Study
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Body Composition
Univariate Analysis of Variance was utilized to examine body composition. Three
response variables (lean body mass, body fat percentage, and WC) were analyzed with univariate
regression adjusted by age, gender, and baseline outcomes.

Lean Body Mass
There was a significant increase in LBM from day one to day thirty (F=5.793, p=0.018).
According to the estimated marginal means of LMB at day thirty, the treatment group had a
higher LBM mean than the placebo group. However, when factoring in age and gender and when
comparing the treatment and control groups in relation to LBM, no significant correlations were
found. Full results can be found in Table 3. See Figure 5.

Body Fat Percentage
Overall, a significant decrease in body fat percent was found (F=527.628, p<0.001).
There was a significant decrease in body fat percent from day one to day thirty (F=2099.220,
p<0.001). According to the estimated marginal means of body fat percent at day thirty, the
treatment group had a higher body fat percentage mean than the placebo group. When factoring
in age and gender and when comparing the treatment and control groups in relation to body fat
percentage, no significant correlations were found. See Figure 6.
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Waist Circumference
Overall, a significant decrease in WC was found (F=145.605, p<0.001). There was a
significant decrease in overall WC from day one to day thirty (F=562.339, p<0.001). According
to the estimated marginal means of WC at day thirty, the treatment group had a lower WC mean
than the placebo group. However, when factoring in age and gender and when comparing the
treatment and control groups in relation to body fat percentage, no significant correlations were
found. See Figure 7.

Table 3: Changes in Body Composition over the Course of the 4-Week Study
Variable
LBM D30

Body Fat % D30

WC D30

Comparison Factor
Overall change
Age
LBM D1
Group
Gender
Group & Gender
Overall change
Age
Body Fat % D1
Group
Gender
Group & Gender
Overall change
Age
WC D1
Group
Gender
Group & Gender

*= statistically significant with p<0.05.

F Value
1.990
0.968
5.793
0.295
0.213
0.133
527.628
0.017
2099.220
0.957
3.341
0.637
145.605
0.601
562.339
0.014
1.118
0.475

Significance Level
0.085
0.327
0.018*
0.588
0.645
0.716
0.000*
0.896
0.000*
0.330
0.070
0.426
0.000*
0.440
0.000*
0.906
0.292
0.492
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Figure 5: Estimated Marginal Means of Lean Body Mass at Day 30

Figure 6: Estimated Marginal of Means of Body Fat Percentage at Day 30
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Figure 7: Estimated Marginal of Means of Waist Circumference at Day 30

MQ Day 1 and MQ Day 30
A Pearson’s correlation was run to determine the relationship between 131 participants’
MQ Day one and MQ day thirty scores. Pearson correlation for the data revealed a strong,
positive correlation between MQ Day One and MQ Day 30 (r=0.690, n=131, p<0.01, two-tails).

Dietary Factors
Diet Compliance
Both treatment and control groups were provided an elimination diet to follow for four
consecutive weeks. The treatment group was found to have 88.9% dietary compliance (n=64),
whereas the placebo group was found to have 98.3% compliance (n=58). Only a total of 6.9%
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non-compliance (n=9) existed for both groups combined. Full results can be found in Table 4.
See Figure 8.

Table 4: Dietary Factors over the Course of the 4-Week Elimination Diet
Factor
Dietary Compliance

Gluten Intolerance

Fluoride Intolerance

Glyphosate Intolerance

Group
Control
Treatment
Total
Control
Treatment
Total
Control
Treatment
Total
Control
Treatment
Total

Total in Group
59
72
131
59
72
131
59
72
131
59
72
131

Number Participants
58
64
122
27
48
75
20
33
53
8
39
47

Dietary Compliance (n=131)

Control (58/122)
Treatment (64/122)
No Compliance (9)

Figure 8: Dietary Compliance over the Course of the 4-Week Study
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Gluten Intolerance
Both treatment and control groups were provided an elimination diet to follow for four
consecutive weeks. The treatment group was found to have 66.7% of participants with gluten
intolerance (n=48), whereas the placebo group was found to have 45.8% of participants with an
intolerance to gluten (n=27). No gluten intolerance was found for 42.7% of both groups
combined (n=56). See Figure 9.

Gluten Intolerance (n=131)
Control (27/75)
Treatment (48/75)
No Intolerance (56)

Figure 9: Gluten Intolerance Discovered During the 4-Week Study

Fluoride Intolerance
From the treatment and control groups, fifty-three participants were found to have
fluoride intolerance. The treatment group was found to have 45.8% fluoride intolerance (n=33),
whereas the placebo group was found to have 34.5% fluoride intolerance (n=20). No Fluoride
intolerance was found for 59.2% of both groups combined (n=77). See Figure 10.
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Fluoride Intolerance (n=131)

Control (21/54)
Treatment (33/54)
No Intolerance (77)

Figure 10: Fluoride Intolerance Discovered During the 4-Week Study

Glyphosate Intolerance
From the treatment and control groups, 47 participants were found to have glyphosate
intolerance. The treatment group was found to have 54.2% glyphosate intolerance (n=39),
whereas the placebo group was found to have 13.8% glyphosate intolerance (n=8). See Figure
11.

Glyphosate Intolerance (n=131)
Control (9/48)
Treatment (39/48)
No Intolerance (83)

Figure 11: Glyphosate Intolerance Discovered During the 4-Week Study

CHAPTER 5

DISCUSSION
This was the first study to test whether food elimination based on ALCAT testing would
alter body composition and decrease body inflammation. Unfortunately, none of the nine
hypotheses tested were supported as evidenced by the results. The findings of this study suggest
both groups had significant decreases for three of the six inflammatory markers, CRP, MPO,
TNF-α. In addition, SAA was found to significantly decrease in the treatment group only.
However, when comparing the treatment and control groups for each inflammatory marker, there
were no significant differences between them. Similarly, both treatment and control groups had
significant decreases for LBM, percentage BF, and WC from day one to day thirty. The findings
of this study concur with other studies in that a decrease in WC is strongly correlated with
decreased levels of CRP (29,30). Previous studies also have found that diet quality was inversely
associated with CRP and SAA levels such that as diet quality improved, levels of CRP and SAA
decreased (21). The findings of this study differ from previous studies that found a significant
treatment effect with reduction in IL-6 and TNF-α based on ALCAT testing and associated
elimination diets (10). Additional studies have shown elimination diets based on ALCAT testing
to significantly improve body composition, specifically decreased body fat percent, and
increased lean body mass (11).
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Inflammatory Markers
Both the treatment group and the control groups experienced significant decreases in
CRP, MPO, and TNF-α; yet, the treatment group was not found to be statistically different than
the control group. Studies have shown that diet induced weight loss decreases CRP, IL-6, TNFα, which may provide some rationale for the observed decreases in CRP & TNF-α along with
improved body composition (20,30). According to Rexrode, et al., CRP is more strongly
correlated with WC than IL-6, which may explain a decrease in CRP and not IL-6 (29,30).
Additionally, the treatment group was found to have a significant decreased in SAA, whereas the
control group showed no significant change in SAA levels. SAA is inversely associated with diet
quality and obesity, where a high quality diet and decrease in adipose tissue was associated with
lower levels of SAA or CRP (21). No significant findings were associated with IL-β-1 and IL-6
for either group.
Overall, there was little evidence to support a treatment effect of elimination diets based
on ALCAT testing on the decreased levels of overall body inflammation. This is most likely due
to the inclusion of chemicals, molds, medicinal herbs, and functional foods, in addition to food
for the elimination diets. It is suspected that lack of knowledge of foods containing these items
decreased dietary compliance. Although not part of the initial focus of this study, an unexpected
and interesting finding was that dietary compliance, and specific intolerances to gluten, fluoride
and glyphosate, may have skewed the final results. Dietary compliance is importance to consider,
especially when analyzing the aforementioned intolerances because the control group was more
compliant (98.3%) than the treatment group (88.9%). In regards to gluten intolerance, about half
of control group were found to have gluten intolerance. Therefore, if told to avoid similar items
(wheat, rye, barley, malt) from green list that are similar or contain gluten, then the avoidance of
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gluten all together will decrease inflammation. This potentially skewed the treatment effect.
Conversely, about half of treatment group was fluoride and glyphosate intolerant. If the
treatment participants were not avoiding tap water (drinking, cooking or adding to foods) or
foods containing glyphosate, this could have also skewed results and decreased the treatment
effect. The skewed results would also occur if the control group, which had a better compliance
rate, was avoiding glyphosate.
Furthermore, because the control group eliminated ingredients found in numerous other
products, total body inflammation decreased; thus creating skewed result of the treatment effect.
For example, sunflower oil is an ingredient found in many commercial food items. In order to
effectively eliminate sunflower oil, fast foods and commercial snack foods also must be
eliminated. Although the individual intolerant to the sunflower oil, eating a healthier, higher
quality diet leads to a reduction of adiposity which can further lead to decreased levels of body
inflammation (2,9,21). Had this not occurred, it is suspected that a significant treatment effect
would have been evident.

Body Composition
Analysis of body composition revealed a significant decrease in lean body mass, body fat
percentage, and WC from day one to day thirty; however, the treatment group was not found to
be statistically different from the control group even after adjustment for age, gender and
baseline outcomes. The findings of this study differ from previous studies that found a
significant positive correlation between elimination diets based on ALCAT testing and improved
body composition (11,14). One reason may be in how the elimination diets for the treatment
group were designed. For example, the treatment group only received a list of foods to avoid
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from the most severe and moderate categories and not the mild category. Had the treatment
elimination diets included the mild category, it is suspected that a significant treatment effect in
regards to decreased inflammation and improved body composition would have been found.
Additionally, the control group received a placebo list of foods to avoid but some lists included
food items that closely resembled or were associated with foods on the participant’s accurate list.
This created mixed results and thus no significant difference between the treatment and control
groups.

Medical Symptom Questionnaire
Comparison of the day one with the day thirty medical symptom questionnaire revealed a
strong, positive correlation between day one and day thirty. Collectively, medical symptomology
improved over the course of the four-week study for a large percentage of the 131 participants.
No analyses were run to determine which group showed the greatest improvement. Similar
studies have examined the relationship of medical symptomology and food sensitivities with a
Disease Symptom Inventory (DSI), however, this study utilized the self-reported Medical
Symptom Questionnaire (MQ) to assess such a relationship (11).

Dietary Factors
In regards to dietary compliance, the control group was found to have a higher percentage
of dietary compliance than the treatment group. This may partly be due to the complexity of the
elimination diets as the diets included foods, functional foods, medicinal herbs, chemicals and
molds. Nutritional education was provided to participants along with the elimination diets to
ascertain foods associated with functional foods, medicinal herbs, chemicals and molds just as
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was done in previous studies (11). Other intolerances to gluten, fluoride, and glyphosate were
present in both groups. Despite offering nutrition education, lack of knowledge or understanding
regarding foods containing gluten and how these chemicals affect certain foods or beverages
may have decreased dietary compliance unknowingly on behalf of the participants.
Approximately 65% of the participants that finished the study completed a 3-day food
log. Due to the lack of return rate, the results were not analyzed as these numbers may not be
entirely representative of the group as a whole.

Conclusion
Overall, there was little evidence to support a treatment effect of elimination diets based
on ALCAT testing on the decrease of overall body inflammation and body composition. This is
most likely due to how the elimination diets were administered, as the items to avoid were vague
and overwhelming, along with poor dietary compliance of the treatment group. Furthermore, it is
suspected that a significant treatment effect in regards to decreased inflammation and improved
body composition would have been found, if the following conditions were met: 1) only
food/beverage items were included in the elimination diets (exclude chemicals, molds, medicinal
herbs, and functional foods, 2) the treatment elimination diets included the mild category and 3)
the placebo lists of foods to avoid were clearly different from the accurate list of foods with no
overlapping food items.

CHAPTER 6

LIMITATIONS AND FUTURE RESEARCH

Limitations
The ALCAT testing consisted of 200 foods, 50 functional foods and medicinal herbs, and
50 chemicals and molds. As a result, the elimination diets were complex; requiring a lot of
education to make sure participants knew exactly foods/beverages were associated with the
functional foods, medicinal herbs, chemicals and molds and thus what to avoid. Future studies
might consider ALCAT testing for foods only to increase participant diet compliance and an
improved treatment effect. It is also recommended that elimination diets specifically list food
items to be avoided to increase diet compliance.
Additionally, mixed treatment results were observed due to conflicting placebo
elimination diets. Many of the placebo elimination diets given to participants in the control group
included items closely related to, or contained in food/beverage items with which the participant
was intolerant. For example, baker’s yeast was on multiple placebo lists where the participants
had gluten as a reactant food on the true results; by eliminating food/beverage items with baker’s
yeast, gluten was also eliminated. This resulted in the participants experiencing a slight treatment
effect as evidenced by decreased MQ day 30 scores. It is recommended that future studies use
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extreme caution when assigning placebo elimination diets so that foods to be avoided during the
course of the study are not associated with true reactant food items.
Conversely, the elimination diets provided to the treatment group were not inclusive
enough. The treatment group received reactant items to avoid from the most severe (red) and the
moderately severe (orange) intolerance lists, but not from the mildly severe (yellow) list. As a
result, more items from the mildly severe list have the chance to be consumed more frequently,
have the potential to become a moderate or severe intolerance and thus create more inflammation
in the body while simultaneously preventing improved body composition. It was also noted that
many participants had extensive mild intolerance lists, yet relatively minimal severe and
moderate intolerance lists. Due to the continued consumption of the mildly intolerant items,
inflammation in the body increased while simultaneously preventing improved body
composition. Both of these circumstances allowed for mixed results of treatment effect.
Participants were asked to maintain their exercise regimen throughout the study based on
the self-reported activity level on the day one exercise log. The pre- and post-study exercise log
was used to ensure this consistency, however, many participants reported changing the exercise
regimen during the study. Additionally, not all participants returned the day thirty exercise log.
Studies using a more accurate protocol to monitor exercise regimen may yield different results.

Future Research
A future study could use the protocol for a four-week elimination diet but simplify the
content of the elimination diet to food/beverage items only. A simpler, more specific list of foods
to eliminate would better assist the participants with dietary compliance. A more inclusive
elimination diet for the treatment group which included severe, moderate and mild reactant foods
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would better encompass the factors suspected to increase inflammation and allow for a more
accurate treatment effect when comparing the control and treatment groups. Future studies could
use the same protocol for Three-Day Food Logs but employ a more stringent plan to increase the
return rate. A future study could use a more accurate protocol to monitor exercise which may
yield different results.
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ATTENTION: Adults 18 to 75 years of age
Do you crave sweets?
Do you experience digestive issues after eating certain foods?
Does your body ache and you cannot figure out why?
If you have answered YES to any of these questions, you might be eligible to participate in a
Nutrition Research Project in Spring 2014
Who’s Requested?
 Males and Females aged 18 years to 65 years of age
 People with food intolerances, nasal stuffiness, chronic tiredness, GERD or eczema.
 People with recurrent anxiety, recurrent depression, insomnia or stressed out
 Exclusion criteria includes pregnant women and people with bleeding disorders
What is Required of You?
 Complete a Disease Symptom Inventory and Medical Symptom Questionnaire
 Complete pre- and post- study blood work & body composition measurements
 Follow an individualized elimination diet for 4 weeks
 Complete 3-day food log and weekly exercise log
Why?
 To determine effect of food elimination on body inflammation and body composition
What are the Benefits to you?
 FREE ALCAT allergy test for 200 foods - $700 value
 FREE individualized elimination diet based on ALCAT test results
 FREE analysis of your diet
 FREE report of body composition measurements using special scale
 FREE lab work to test the level of inflammation in your body - $1,000 value
Who to Contact?
 Dawn Herbig at elimdietstudy@yahoo.com
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THE DISEASE SYMPTOM INVENTORY (DSI)
Please rate each of the following disease symptoms for the extent to which they are
currently bothering you using the following rating scale:
0 = I do NOT have this symptom
2 = A Mild Effect
4 = A Severe Effect

1 = A Very Mild Effect
3 = A Somewhat Severe Effect
5 = An Extremely Severe Effect

1. _____ Migraine Headaches

15. ____ Lack of Energy

2. _____ Irritable Bowel Syndrome

16. ____ Food Allergies

3. _____ Inflammatory Arthritis

17. ____ Feeling Under Stress

4. _____ Gastro Esophageal Reflux

18. ____ Craving for Sweets

5. _____ Recurrent Sinusitis with Infection

19. ____ Cravings for Foods other than

6. _____ Tension Fatigue Syndrome

Sweets

7. _____ Eczema

20. ____ Anorexia

8. _____ Recurrent Anxiety

21. ____ Bulimia

9. _____ Recurrent Depression

22. ____ Overeating

10. ____ Insomnia

23. ____ Other (write in:

11. ____ Low Self-Esteem

____________________________________)

12. ____ Chronic Tiredness

24. ____ Other (write in:

13. ____ Binge Eating

___________________________________)

14. ____ Chronic Tension

APPENDIX C
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Medical Symptom Questionnaire
Name _____________________________

Date _________________

Rate each of the following symptoms based upon your typical health profile for:
 Past 30 days
 Past 48 hours

Point Scale

0
1
2
3
4

HEAD

________
________
________
________

Headaches
Faintness
Dizziness
Insomnia

EYES

________
________
________
________

Watery or itchy eyes
Swollen, reddened or sticky eyelids
Bags or dark circles under eyes
Blurred or tunnel vision
(does not include near or far-sightedness) Total ________

EARS

________
________
________
________

Itchy ears
Earaches, ear infections
Drainage from ear
Ringing in ears, hearing loss

Total ________

________
________
________
________
________

Stuffy nose
Sinus problems
Hay fever
Sneezing attacks
Excessive mucus formation

Total ________

________
________
________
________
________

Chronic coughing
Gagging, frequent need to clear throat
Sore throat, hoarseness, loss of voice
Swollen or discolored tongue, gums, lips
Canker sores

Total ________

________
________
________
________
________

Acne
Hives, rashes, dry skin
Hair loss
Flushing, hot flashes
Excessive sweating

Total ________

________
________
________

Irregular or skipped heartbeat
Rapid or pounding heartbeat
Chest pain

Total ________

NOSE

MOUTH/THROAT

SKIN

HEART

-

Never or almost never have the symptom
Occasionally have it, effect is not severe
Occasionally have it, effect is severe
Frequently have it, effect is not severe
Frequently have it, effect is severe

Total ________
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LUNGS

________
________
________
________

Chest congestion
Asthma, bronchitis
Shortness of breath
Difficulty breathing

Total ________

________
________
________
________
________
________
________

Nausea, vomiting
Diarrhea
Constipation
Bloated feeling
Belching, passing gas
Heartburn
Intestinal/stomach pain

Total ________

________
________
________
________
________

Pain or aches in joints
Arthritis
Stiffness or limitation of movement
Pain or aches in muscles
Feeling of weakness or tiredness

Total ________

________
________
________
________
________
________

Binge eating/drinking
Craving certain foods
Excessive weight
Compulsive eating
Water retention
Underweight

Total ________

ENERGY/ACTIVITY ________
________
________
________

Fatigue, sluggishness
Apathy, lethargy
Hyperactivity
Restlessness

Total ________

________
________
________
________
________
________
________
________

Poor memory
Confusion, poor comprehension
Poor concentration
Poor physical coordination
Difficulty in making decisions
Stuttering or stammering
Slurred speech
Learning disabilities

Total ________

________
________
________
________

Mood swings
Anxiety, fear, nervousness
Anger, irritability, aggressiveness
Depression

Total ________

________
________
________

Frequent illness
Frequent or urgent urination
Genital itch or discharge

DIGESTIVE TRACT

JOINTS/MUSCLE

WEIGHT

MIND

EMOTIONS

OTHER

Total ________
GRAND TOTAL

TOTAL _________
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ALCAT Screening & Ethnicity Form

NAME_____________________________________

Please list the medications you are currently taking__________________________________
____________________________________________________________________________

Please list any food allergies you have ________________________________________________
_____________________________________________________________________

Please list any food sensitivities or intolerances you have__________________________________
________________________________________________________________________________

Ethnicity:
_____ American Indian or Alaska Native
_____ Asian
_____ Black or African American
_____ Caucasian
_____ Hispanic
_____ Native Hawaiian or Other Pacific Islander
_____ Other: ______________________

APPENDIX E
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3-Day Food Recall
Name: __________________________
For the following sheet, please do the following:
 Indicate the time of consumption in the left column
 Indicate the foods consumed along with estimated measurements (cup, ounce,
tablespoon, etc.) in the right column.
 Include 2 weekdays and 1 weekend day.
 Please complete each day on a separate sheet.
Time:
7:45 am

Food Consumed & Amount
1 whole egg with 2 egg equivalents of egg beaters
2 slices of Brownberry 12-Grain bread
2 Tbsp Skippy peanut butter
8 oz 1% milk
8 oz Folgers coffee with 2 Tbsp of hazelnut coffee creamer
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Exercise Log
For the following sheet, please do the following:
 Indicate the date of exercise in the left column
 Indicate the exercise(s) completed along with number of sets and repetitions in each set in
the right column.
Date:
August 13, 2013

Exercise(s) Completed:
3-mile run at 10:15 pace
4 sets of abdominal crunches, 8 reps each set
2-mile walk at moderate pace
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Consent to Participate in the Food Elimination Based on ALCAT Testing and the Effect on
Overall Body Inflammation Study
You have been invited to participate in a research project sponsored by manufacturer of the
ALCAT test and designed to test the effect of food elimination on body inflammation and body
composition. The ALCAT test is a food sensitivity test, and is not equivalent to medical allergy
testing. You should continue to avoid foods that you know you have allergies or intolerances,
regardless, of the ALCAT test results. This study is being conducted by Dr. Judith Lukaszuk, an
Associate Professor in Nutrition and Dietetics at Northern Illinois University and Dawn Herbig,
a graduate level nutrition student and Dietetic Intern at NIU.
If you meet the requirements of this study to be determined by completion of disease symptom
inventory, you will be asked to follow an individualized elimination diet based on ALCAT
testing for four weeks. Your four weeks will begin about one week following your initial
screening for this study. You will be provided with a list of foods to avoid for four weeks. You
will be randomly assigned to either a control or intervention group. The control group will
receive “false” ALCAT reports on their food sensitivities, whereas, the intervention group will
receive accurate ALCAT report results. At the end of the study the control group will be
provided with accurate ALCAT report results. On day 1 of the study 25 mL (or 5 teaspoons) and
at the end of the study, 21.5 mL (or a little over 4 teaspoons) of your blood will be taken to
assess food intolerances and to assess nine inflammatory markers: C-Reactive Protein (CRP),
Fibrinogen, Interleukin-1 beta (IL-1 beta), Interleukin-6 ( IL-6), Myeloperoxidase (MPO),
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), Serum Amyloid A (SAA),
Tumor Necrosis Factor alpha (TNF-alpha), and Zonulin. You will report to the nutrition
laboratory at NIU and have your height, weight, body fat percentage, lean body mass and
abdominal waist circumference measured at baseline and at the end of the study. All body
measurements will be taken with subjects in light weight clothing and bare feet. Height will be
measured using a wall-mounted stadiometer. Weight, fat mass, percent fat, and fat free mass will
be assessed using bioelectrical impedance scale called Biospace. Abdominal circumference will
be measured with a cloth tape anteriorly halfway between the lowest lateral portion of the
ribcage and the iliac crest. You must be willing to complete a Medical Symptoms questionnaire
at the beginning and end of the study as well as 12 weeks after study completion. You can fill in
the form via e-mail and send it back to Dr. Judith Lukaszuk at jmlukaszuk@niu.edu. You will
also be asked to keep a keep a weekly 3 day food record (2 weekdays and 1 weekend day) and an
exercise log during the study. We will also be providing you with a questionnaire which asks
you your ethnicity, what medications you are taking, and what food allergies or food intolerances
you may have.
You understand that participation in this study will involve elimination of specific foods based
on ALCAT test results for the duration of the four-week study. The elimination diets will be
individualized for you based on the blood drawn on day one and used for the ALCAT test. The
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blood draw will take approximately 15-20 minutes to complete. The anthropometric
measurements will take about 20 to 30 minutes to complete.
You are aware that participation is voluntary and may be withdrawn at any time without penalty
or prejudice, and that if you have any additional questions concerning this study, you may
contact Dr. Judith Lukaszuk at (815) 753-6352 or Dawn Herbig (847) 927-7808. You understand
that if you wish further information regarding my rights as a research subject, you may contact
the Office of Research Compliance at Northern Illinois University at (815) 753-8588.
You understand that the intended benefits of this study include information of the effects of food
elimination on body inflammation and body composition. You understand that participation in
this study is free and you will not be monetarily compensated although you will receive valuable
information regarding what foods you are intolerant to and how much inflammation you have in
your body based on the foods you consume.
You understand that there is the potential risk of infection at the site of the blood draw. There is
also a chance you may feel dizzy or light headed during the blood draw. Please tell us about
these symptoms. We will require you to sit in the chair until your symptoms go away. If your
symptoms do not go away in 5 minutes you will be provided with fruit juice to drink. You also
may ask to stop the blood draw at any time if you feel uncomfortable with the blood draw
procedure. Northern Illinois University policy does not provide for compensation for, nor does
the University carry insurance to cover injury or illness incurred as a result of participation in
University sponsored research projects. Upon suffering a minor injury, subjects will be referred
to their PCP or nearest hospital and in the event of serious injury emergency medical services
will be notified immediately.
You understand that all information gathered during this study will be kept confidential by
giving all participants a number that is representative of them, and storing the information in a
confidential file cabinet, which is locked when not in use. The four-week elimination program
results information will only be accessible by the researcher and the advisor.
I understand that my signature below is consent to participate in the Food Elimination Based
on ALCAT Testing and the Effects on Body Inflammation and Body Composition Study. I
understand that my consent to participate does not constitute a waiver of any legal rights or
redress I might have as a result of my participation, and I acknowledge that I have received a
copy of this form.
Printed name: _________________________________________________________________
Signature: ______________________________________________ Date: _________________
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FOOD ELIMINATION BASED ON ALCAT TESTING AND THE EFFECT ON
OVERALL BODY INFLAMMATION

Debriefing Letter for Control Group Participants
You were randomly assigned to the control group and as such were provided “false” ALCAT
report results at the beginning of the study. Attached are your accurate ALCAT report results.
Foods included in the red column (indicates a severe intolerance and should be avoided for 6
months), orange column (indicates a moderate intolerance should be avoided for 3-6 months) and
yellow column (indicates a mild intolerance should be avoided if possible) should be avoided
and foods in the green column indicates acceptable foods so you can eat these foods as long as
you are not allergic to them or have from previous experience with these food reacted with a
food intolerance. The ALCAT Company will send out a test results guide booklet, a wallet size
results card and a meal plan for you to follow based on your ALCAT test results. However, you
should consult with your physician before eliminating any foods long term.
Acknowledgement:
I, ________________________________, have received my accurate personalized ALCAT test
results and understand the foods I need to avoid to potentially reduce inflammation in my body.

Signature: ___________________________________________ Date: ___________________
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FOOD ELIMINATION BASED ON ALCAT TESTING AND THE EFFECT ON
OVERALL BODY INFLAMMATION

Debriefing Letter for Intervention Group Participants
You were randomly assigned to the intervention group and as such was provided “accurate”
ALCAT report results at the beginning of the study. Foods included in the red column
(indicates a severe intolerance and should be avoided for 6 months), orange column (indicates a
moderate intolerance should be avoided for 3-6 months) and yellow column (indicates a mild
intolerance should be avoided if possible) should be avoided and foods in the green column
indicates acceptable foods so you can eat these foods as long as you are not allergic to them or
have from previous experience with these food reacted with a food intolerance. The ALCAT
Company will send out a test results guide booklet, a wallet size results card and a meal plan for
you to follow based on your ALCAT test results. However, you should consult with your
physician before eliminating any foods long term.
At the conclusion of the study, the participants in the control/placebo group will be un-blinded
and provided with their ALCAT tests results to determine foods they have sensitivities to and
therefore need to avoid.
Acknowledgement:
I, ________________________________, have received my accurate personalized ALCAT test
results and understand the foods I need to avoid to potentially reduce inflammation in my body.

Signature: ___________________________________________ Date: ___________________

APPENDIX J
PARTICIPANT’S MEASUREMENT SHEET
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Participant #:_______

Measurement
Waist Circumference
Height

Measurement
Body Fat %
Lean body Mass
Weight

Anthropometric Measurements
Day One
Day 30

Body Composition
Day One

Day 30

